| Dragonfly Pediatric Speech Therapy | |
|
9000 E Nichols Ave Ste 140, Centennial, CO 80112-3406 | |
| (720) 515-8254 | |
| (720) 575-9914 |
| Full Name | Dragonfly Pediatric Speech Therapy |
|---|---|
| Type | Facility |
| Speciality | Speech-language Pathologist |
| Location | 9000 E Nichols Ave Ste 140, Centennial, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467143982 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | (* (Not Available)) | Secondary |
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dragonfly Pediatric Speech Therapy 9000 E Nichols Ave Ste 140, Centennial, CO 80112-3406 Ph: (720) 515-8254 | Dragonfly Pediatric Speech Therapy 9000 E Nichols Ave Ste 140, Centennial, CO 80112-3406 Ph: (720) 515-8254 |
News Archive
Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.
Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.
American Civil Liberties Union on behalf of the Sexuality Information and Education Council of the United States and Advocates for Youth on Thursday sent a letter to HHS Secretary Mike Leavitt saying that the agency should enforce a federal law that states abstinence education must include "medically accurate" information about condom effectiveness, the Washington Times reports (Wetzstein, Washington Times , 4/27).
The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.
› Verified 2 days ago
Ms. Donna V Swanson, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6771 S Washington St, Centennial, CO 80122 Phone: 917-403-6550 | |
Esther Duke, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5000 E Arapahoe Rd, Centennial, CO 80122 Phone: 303-552-0215 | |
Mary-frances Steagall Emerson, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9137 E Mineral Cir Ste 120, Centennial, CO 80112 Phone: 303-284-4021 | |
Elizabeth Lee Huber, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7854 S Ulster St, Centennial, CO 80112 Phone: 720-665-5283 | |
Kathleen Smith, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 19993 E Long Ave, Centennial, CO 80016 Phone: 720-886-3550 | |
Rebecca Rehn, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6851 S Holly Cir, Centennial, CO 80112 Phone: 720-542-8737 | |
Kailey Silliman, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6851 S Holly Cir, Centennial, CO 80112 Phone: 720-542-8737 |